Wolfram Malter

Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial

Ulrike Nitz, Oleg Gluz, Matthias Christgen et al. · Breast Cancer Research and Treatment · 2017 · 183 citations · Full text

West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast Cancer

Ulrike Nitz, Oleg Gluz, Michael Clemens et al. · Journal of Clinical Oncology · 2019 · 144 citations

De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR–): survival outcomes from a multicentre, open-label, randomised, phase 2 trial

Ulrike Nitz, Oleg Gluz, Monika Graeser et al. · The Lancet Oncology · 2022 · 76 citations

Breast Oncology, Medicine, Trastuzumab Therapy +9

Diagnosing Pathologic Complete Response in the Breast After Neoadjuvant Systemic Treatment of Breast Cancer Patients by Minimal Invasive Biopsy

Joerg Heil, André Pfob, Hans‐Peter Sinn et al. · Annals of Surgery · 2020 · 60 citations

Surgical Oncology, Breast Oncology, Pathologic Complete Response +20

Differential impact of prognostic parameters in hormone receptor–positive lobular breast cancer

Matthias Christgen, Oleg Gluz, Nadia Harbeck et al. · Cancer · 2020 · 53 citations · Full text